Journal
EUROPEAN JOURNAL OF NEUROSCIENCE
Volume 51, Issue 12, Pages 2412-2422Publisher
WILEY
DOI: 10.1111/ejn.14679
Keywords
dyskinesia; l-DOPA; LY-487; 379; mGlu(2) receptor; Parkinson's disease; positive allosteric modulator
Categories
Funding
- Fonds de Recherche du Quebec - Sante
- Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
- Michael J. Fox Foundation for Parkinson's Research
- Parkinson Canada
- Weston Brain Institute
- Healthy Brains for Healthy Lives
Ask authors/readers for more resources
l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson's disease (PD), but its use over a long period is marred by motors complications such as dyskinesia. We previously demonstrated that selective metabotropic glutamate 2/3 (mGlu(2/3)) receptor activation with LY-354,740 alleviates dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset and the 6-hydroxydopamine (6-OHDA)-lesioned rat. Here, we sought to determine the role played by selective mGlu(2) activation in the anti-dyskinetic effect of mGlu(2/3) stimulation and have investigated the effect of the highly selective mGlu(2) positive allosteric modulator LY-487,379 at alleviating established, and preventing the development of, l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat. First, dyskinetic 6-OHDA-lesioned rats were administered l-DOPA in combination with LY-487,379 (0.1, 1 and 10 mg/kg) or vehicle, and the severity of dyskinesia was determined. Second, 6-OHDA-lesioned rats were administered LY-487,379 (0.1 or 1 mg/kg), started concurrently with l-DOPA, once daily for 22 days, and dyskinesia severity was evaluated weekly for four consecutive weeks. We also assessed the effect of LY-487,379 on l-DOPA anti-parkinsonian effect. We found that acute challenges of LY-487,379 0.1 mg/kg in combination with l-DOPA, significantly diminished dyskinesia severity, by approximate to 54% (p < .01), when compared to vehicle. Moreover, animals treated with l-DOPA/LY-487,379 0.1 and 1 mg/kg during the dyskinesia induction phase exhibited milder dyskinesia, by approximate to 74% and approximate to 61%, respectively (both p < .01), when compared to l-DOPA/vehicle. LY-487,379 did not impair l-DOPA anti-parkinsonian activity. These results suggest that mGlu(2) activation may be an effective and promising therapeutic strategy to alleviate the severity and prevent the development of dyskinesia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available